Editas Medicine Inc
NASDAQ:EDIT
Editas Medicine Inc
EPS (Diluted)
Editas Medicine Inc
EPS (Diluted) Peer Comparison
Competitive EPS (Diluted) Analysis
Latest Figures & CAGR of Competitors
Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Editas Medicine Inc
NASDAQ:EDIT
|
EPS (Diluted)
-$2
|
CAGR 3-Years
-1%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
EPS (Diluted)
$2
|
CAGR 3-Years
0%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
1%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
EPS (Diluted)
$0
|
CAGR 3-Years
18%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
-18%
|
|
Amgen Inc
NASDAQ:AMGN
|
EPS (Diluted)
$12
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
7%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
EPS (Diluted)
$13
|
CAGR 3-Years
11%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
EPS (Diluted)
$34
|
CAGR 3-Years
4%
|
CAGR 5-Years
10%
|
CAGR 10-Years
23%
|
See Also
What is Editas Medicine Inc's EPS (Diluted)?
EPS (Diluted)
-2
USD
Based on the financial report for Dec 31, 2023, Editas Medicine Inc's EPS (Diluted) amounts to -2 USD.
What is Editas Medicine Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
3%
Over the last year, the EPS (Diluted) growth was 37%. The average annual EPS (Diluted) growth rates for Editas Medicine Inc have been -1% over the past three years , 3% over the past five years .